Thu, Oct 23, 2014, 10:29 AM EDT - U.S. Markets close in 5 hrs 31 mins


% | $
Quotes you view appear here for quick access.

ImmunoCellular Therapeutics, Ltd. Message Board

horse.ghost25 6 posts  |  Last Activity: Jul 24, 2014 3:13 PM Member since: Sep 14, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    catalysts coming

    by horse.ghost25 Jul 24, 2014 9:17 AM
    horse.ghost25 horse.ghost25 Jul 24, 2014 3:13 PM Flag

    it doesn´t make any sense to use the two drugs (Doxo plus Ifo) if you have the same result with one drug (Aldo) with significant less sideeffects.

    Sentiment: Strong Buy

  • Reply to


    by bnarayan_97 Jul 24, 2014 9:55 AM
    horse.ghost25 horse.ghost25 Jul 24, 2014 10:04 AM Flag

    yep, CYTR trial results have been stellar good.

    Sentiment: Strong Buy

  • horse.ghost25 by horse.ghost25 Jul 24, 2014 9:17 AM Flag

    remember the catalyst coming : they will push the pps to double digits.
    until now the trial data was stellar good and probably will remain to be .
    -- Initiate a global Phase 2b clinical trial of aldoxorubicin as a second-line treatment for small cell lung cancer (SCLC) in the second half of 2014
    -- Announce OS results from the ongoing global Phase 2b clinical trial of aldoxorubicin as a first-line treatment for STS in the second half of 2014
    -- Expand the oncology pipeline by combining the Company’s novel linker platform technology with additional chemotherapeutic agents
    -- Announce preliminary results from the ongoing Phase 2 clinical trial of aldoxorubicin in Glioblastoma Multiforme in the coming year.

    Sentiment: Strong Buy

  • almost a third of the volume sold short on July 22 and 23. Some BOYZ are trying hard to hold pps down. More and more investors will realize the value of CYTX technology. There will be more good news coming in the next months. Good time to accumulate .

  • horse.ghost25 horse.ghost25 Jul 23, 2014 3:32 PM Flag

    more and more investors will realize the technology of CYTX.

    Roth Capital analyst Joseph Pantginis reiterated a Buy rating on CYTX with a $10 price target.

    Pantginis noted, “We see the selection of Cytori’s ADRC’s for the CCTRN’s trial as validating for the company. The CCTRN is supported by the National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH). The randomized, Phase I trial in end-stage ischemic heart disease will include a ~10 patient open-label phase followed by a safety committee review, and then a ~24 patient randomized phase. Also validating for the company was BARDA’s recent notice of intent to exercise Option 1 of its contract with Cytori, which could be worth up to $35 million in non-dilutive funding to CYTX. Focus remains on the ATHENA Phase II program in chronic heart failure. ATHENA-I has 26 patients enrolled (target 45 by year end) and ATHENA-II has 3 patients enrolled. The study is enrolling 2-4 patients per month and the FDA has allowed expanding the number of clinical trial sites from 8 to 10 in ATHENAI and 10 to 12 in ATHENA-II. ATHENA-I data could read out in the mid-2015 time frame and management is encouraged by current enrollment trends”.

    Sentiment: Strong Buy

  • horse.ghost25 by horse.ghost25 Jul 23, 2014 10:40 AM Flag

    charts signals a change to the upside.

    Sentiment: Strong Buy

0.6903-0.0048(-0.69%)10:28 AMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.